Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 65 and up

Lemborexant to help Sleep and Delirium in older ICU patients

Official title: Lemborexant for Sleep Promotion and Delirium Prevention in Critically Ill Adults: A Combined Feasibility-Pilot, Randomized, Double-Blind, Placebo-Controlled Trial

Run by Mahidol University · NCT07407400 · Data updated 2026-11-12

This study tests whether lemborexant, a sleep medication, helps improve sleep and reduce delirium in adults 65 and older in the ICU.

More Critical Illness trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages65 Years and up
SexAll
Enrollment100 (estimated)
SponsorMahidol University
Academic / other
Locations1 site (Bangkok)
StatusRecruiting
StartedSeptember 1, 2026
Main results expectedDecember 31, 2027
Study endsJune 30, 2028
Registry record updatedOctober 8, 2026
Trial IDNCT07407400 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 65 or older admitted to the Surgical ICU with an anticipated stay of at least 48 hours and able to receive enteral medication.

Probably not a fit

Patients with frequent neurological checks, deep sedation, recent CAM-ICU positivity, severe instability, high aspiration risk, or those on certain interacting medications may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 4, single-center trial will compare lemborexant to placebo in elderly surgical ICU patients who have at least 48 hours of expected stay. The study focuses on sleep quality and delirium outcomes, with safety monitored in a critically ill population. Eligible participants must be able to take medications by mouth or via a tube and meet specific health criteria. The trial aims to determine if this sleep drug can be safely used in the SICU to potentially improve recovery.

Why it matters

Potential benefit: If successful, patients may experience better sleep and a lower risk of delirium during their ICU stay.

How similar studies have gone: Previous sleep aids have shown mixed results in ICU patients; this study explores a targeted dual orexin receptor antagonist in a critically ill elderly population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 65 years or older.
* Admission to the Surgical Intensive Care Unit (SICU).
* Anticipated ICU stay of at least 48 hours, as assessed by the ICU consultant and responsible surgeon.
* Able to receive enteral medication via oral or nasogastric route.

Exclusion Criteria:

* Requirement for frequent neurological checks or scheduled awakening (e.g., acute stroke or neurosurgery).
* Deep sedation defined as Richmond Agitation-Sedation Scale (RASS) ≤ -3.
* Positive Confusion Assessment Method for the ICU (CAM-ICU) within 12 hours prior to randomization.
* Severe hemodynamic or respiratory instability requiring neuromuscular blockers or high-dose vasopressors (e.g., norepinephrine ≥ 0.1 µg/kg/min and titrating upward).
* High risk of aspiration, including ongoing vomiting, gastric residual volume \>250 mL, or intolerance to oral or enteral medications.
* Concomitant use of strong CYP3A inhibitors or inducers (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, rifampicin, carbamazepine, phenytoin, or St. John's wort).
* Severe hepatic impairment (Child-Pugh class C).
* End-stage kidney disease or chronic kidney disease stage 5.
* Concomitant use of sedative-hypnotic medications, including benzodiazepines, Z-drugs, trazodone, tricyclic antidepressants, melatonin, or other sleep-inducing agents.
* Known hypersensitivity to lemborexant or other dual orexin receptor antagonists.
* History of cataplexy-like symptoms or severe depression with suicidal ideation.

Where it's running

  • Siriraj Hospital
    Bangkok, Thailand
    Recruiting

Study contacts

  • Principal investigator: Nuanprae Kitisin — Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University
  • Study coordinator: Nuanprae Kitisin, MD
  • Email: nuanprae.kit@mahidol.ac.th
  • Phone: +66896767706

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.